AVI-4557 is an oral antisense compound that selectively inhibits the metabolic enzyme cytochrome P450 3A4 (CYP), a liver enzyme responsible for the metabolism or breakdown of approximately half of currently... Studies indicate that AVI-4557 can successfully reduce the rate of metabolism for certain drugs, therefore allowing greater and longer availability of the drug in the patient's system through a decrease in clearance and an increase...
- Mechanism
- Curator reviewed
selectively inhibits the metabolic enzyme cytochrome P450 3A4 (CYP), a liver enzyme responsible for the metabolism or breakdown of approximately half of currently marketed drugs. S
- Primary indication
- Investigated for use/treatment in adverse effects (chemotherapy) and adverse effects (drug).Curator reviewed
- Code names
- AVI-4557
Resolves to
What you can answer from here — as of April 02, 2025
Which drugs share a target with AVI-4557, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account